Enliven Therapeutics ELVN Unrealized gains (losses) on available-for-sale securities
Unrealized gains (losses) on available-for-sale securities at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax.
The official record: Enliven Therapeutics’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Enliven Therapeutics's unrealized gains (losses) on available-for-sale securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Enliven Therapeutics's unrealized gains (losses) on available-for-sale securities?
- Enliven Therapeutics (ELVN) reported unrealized gains (losses) on available-for-sale securities of -$716K in Q1 2026.
- How has Enliven Therapeutics's unrealized gains (losses) on available-for-sale securities changed year-over-year?
- Enliven Therapeutics's unrealized gains (losses) on available-for-sale securities decreased by 908.5% year-over-year, from -$71K to -$716K.
- What is the long-term trend for Enliven Therapeutics's unrealized gains (losses) on available-for-sale securities?
- Over 4 years (2021 to 2025), Enliven Therapeutics's unrealized gains (losses) on available-for-sale securities has grown at a 93.3% compound annual growth rate (CAGR), from -$20K to $279K.
- What does unrealized gains (losses) on available-for-sale securities mean?
- This metric captures the unrealized changes in the fair value of investment securities classified as available-for-sale that are not yet recognized in net income. It reflects market-driven fluctuations in the value of the company's liquid asset portfolio, such as debt or equity instruments held for investment purposes. Monitoring this helps investors understand the volatility of the company's treasury assets outside of core operating performance.